Microfluidic technology can realize the rapid separation of blood exosomes83, 84, 85; in particular, microfluidic technology can validate significant biomarkers, such as folate receptor alpha (FRα) in plasma exosomes from ovarian cancer patients86 and hepatocyte growth factor (HGF), STAT3, and interleukin 6 (IL-6) in serum exosome samples from early-stage HGSOC patients.87 Here, FOLR1 is linked to ovarian carcinoma.